about
Current Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionVaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding SiteInduction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy.Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and MacaquesWhich Antibody Functions are Important for an HIV Vaccine?Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination.Increased generation of HIV-1 gp120-reactive CD8+ T cells by a DNA vaccine construct encoding the chemokine CCL3.Neutralizing antibodies inhibit HIV-1 infection of plasmacytoid dendritic cells by an FcγRIIa independent mechanism and do not diminish cytokines production.Sex-based differences in HIV type 1 pathogenesisMucosal immunity in the female genital tract, HIV/AIDSIn pursuit of an HIV vaccine: an interview with Andrew McMichael.Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells.Thirty years on: HIV receptor gymnastics and the prevention of infectionDesign, synthesis, biochemical, and antiviral evaluations of C6 benzyl and C6 biarylmethyl substituted 2-hydroxylisoquinoline-1,3-diones: dual inhibition against HIV reverse transcriptase-associated RNase H and polymerase with antiviral activities.Allosteric induction of the CD4-bound conformation of HIV-1 Gp120.Engineering and exploitation of a fluorescent HIV-1 gp120 for live cell CD4 binding assaysCapacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-DependentThe Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single InfectionChemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer AntigensPotential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved AntigensThe Quest for an HIV-1 Vaccine Adjuvant: Bacterial Toxins as New Potential Platforms.The Art of HIV Elimination: Past and Present Science.Vaccine-induced measles virus-specific T cells do not prevent infection or disease but facilitate subsequent clearance of viral RNA.Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.Human immunodeficiency virus antibodies and the vaccine problem.Modeling T cell responses to antigenic challenge.Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs.An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine.Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation.A novel approach for addressing diseases not yielding to effective vaccination? Immunization by replication-competent controlled virus.Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes.Increased Steady-State Memory B Cell Subsets Among High-Risk Participants in an HIV Vaccine Trial.HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein.A Plant-Derived Multi-HIV Antigen Induces Broad Immune Responses in Orally Immunized Mice.Functional conservation of HIV-1 Gag: implications for rational drug design.Emerging Targets for Developing T Cell-Mediated Vaccines for Human Immunodeficiency Virus (HIV)-1.Novel Therapeutic Approach for Inhibition of HIV-1 Using Cell-Penetrating Peptide and Bacterial Toxins.A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system.
P2860
Q26775082-F89AEC36-010B-4F8D-8B59-0E1BDD651AA5Q27319450-7875E049-BB87-490F-B03B-A5136269337CQ33611645-1188F3BB-B1A4-4B2E-8257-097A5F246683Q33683203-64FD7A23-EC7A-4057-BA48-A76BBA95E491Q33772637-130BFA75-40E8-406E-8BD7-A3244C0F39CAQ34022578-F055DAC1-13F7-4F5A-919B-8F573A12E7A2Q34046807-75E029D5-3F4B-4F66-AA18-15B5196F9051Q34055377-880C0038-3032-4FE3-9974-D73BCADBC87BQ34148475-43A864C7-D7A0-4B44-B135-1D0F2DA9F9DAQ34275424-464120FE-A493-4AA8-BF24-141564B95FC9Q34345870-D29145C3-C10C-45CA-BF19-4D49369D1CDBQ34555891-07170381-6029-40D1-98EB-9826C4721E56Q34594624-7F80DD14-165A-4502-9B63-DAB599517003Q34732816-486549B1-B988-4D36-8280-BE1BB6735942Q35013490-F3893053-09AC-4B4E-B499-642745462D09Q35058860-3AC7284B-0876-4EF2-9892-D972E95F4D48Q35070898-335C7BAF-112A-43D4-9668-7DFE47F972B1Q35686912-D258FAD6-7A24-47F6-B23D-4A1E36C289CDQ35686970-80291EA6-31A2-4C1B-BDF6-F68198991DF7Q36434196-727B40CD-E277-47F3-A271-12C6B8AE235BQ36736400-95A1E8C4-2C77-4556-9B3D-0DB0B4F5DE5BQ37057983-02AEECDF-3649-4FB7-94E3-5B94ACD7E19CQ37354106-5A0759A8-D0F0-40E0-976E-7D705C84DC8DQ37714080-4128BC23-4606-4635-A671-C3CCF93C0453Q37729781-69444F09-6E78-42A5-AD02-1F4C59D7DEB6Q38192126-CF2D2834-069B-4721-B890-BDB095B3A64FQ38255612-5C7F36B9-70AC-418C-A99B-FBF920A9F2D8Q38260862-07DF7733-D172-4D1E-8954-0475856F809EQ38283531-06EA881F-DE22-4302-8FD4-36669415849DQ38296086-2CC19EC5-291A-48D3-A3CF-FCA2EF731114Q38353693-EA7F6D07-BCBF-4883-B94E-5F182672BA13Q39407795-B6DEE24E-FE1F-451E-92A5-4EE4020EA595Q40442031-F050E67D-0AB8-44AD-80A2-9FDC231CDD29Q40545310-37435360-AF2C-4D6D-B42A-91F1A34B9EEFQ41138686-248A847F-5300-4D36-8170-831C2102261FQ41424896-22E26AD4-9028-4FAD-8E59-67ED6BFBFB29Q41822002-E7111BCE-4688-4FF2-9581-6937D575FE15Q45325097-67812277-B013-407E-A392-D558FF0C99E8Q47144668-29D0D2F1-AE1E-4E7F-AC20-5CEF7AFF75FEQ47549087-11172956-E61A-4047-AD53-51324780FE01
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of prophylactic vaccines against HIV-1.
@en
Development of prophylactic vaccines against HIV-1.
@nl
type
label
Development of prophylactic vaccines against HIV-1.
@en
Development of prophylactic vaccines against HIV-1.
@nl
prefLabel
Development of prophylactic vaccines against HIV-1.
@en
Development of prophylactic vaccines against HIV-1.
@nl
P2860
P921
P356
P1433
P1476
Development of prophylactic vaccines against HIV-1
@en
P2093
Lucy Dorrell
P2860
P2888
P356
10.1186/1742-4690-10-72
P5008
P577
2013-07-17T00:00:00Z
P5875
P6179
1048789717